Hypoxia-inducible Factor-1 (HIF-1) Regulated Circulating Angiogenic Cells (CACs) Recruitment in Burn Wound Healing

NCT ID: NCT00796627

Last Updated: 2017-09-29

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2014-04-30

Brief Summary

This research is being done to increase knowledge about wound healing and different factors that may affect healing in burn patients.

Detailed Description

Burn injuries represent a major public health problem, requiring medical attention for more than one million Americans annually. Despite therapeutic advances, non-healing burn wounds and excessive scarring still result in significant long term physical and psychosocial morbidity. In this study we propose to perform clinical and research to study the role of circulating angiogenic cells (CAC) in promoting burn wound healing.

CAC's have been shown to contribute to vascularization and tissue repair in a number of animal models of tissue injury ischemia and mobilization of CACs into the peripheral blood has been demonstrated in burn wound patients.

We hypothesize that primary healing of burn wounds is dependent on repair of damaged vasculature, and that bone marrow derived stem cells, circulating angiogenic cells (CAC), play a critical role in the healing process. Furthermore we propose that the transcription factor Hypoxia Inducible Factor 1 alpha (HIF 1 alpha) through production of peptide products of its downstream target genes directs the "homing" of CAC's to the wound where they participate in healing events. The first aim of this study is to correlate mobilization of CAC's into the blood stream with the success of burn wound healing.

CAC's have been shown to contribute to vascularization and tissue repair in a number of studies. The relationship between mobilization of CAC's and burn wound healing has not been examined. In addition to surveying CAC numbers in the peripheral blood, we will assay levels of the putative mediators of CAC mobilization: Vascular Endothelial Growth Factor (VEGF), Placenta Growth Factor (PLGF), and Stromal Cell-Derived Factor (SDF-1). We hypothesize that individuals who are able to mount a large and sustained mobilization of CAC's into the peripheral blood from the bone marrow, will be more likely to heal the injured vasculature and go on to primary healing. Individuals with an inadequate mobilization of CAC's will fail to repair the damaged vasculature in the wound and proceed to necrosis and "conversion" to third degree, necrotic burn wounds.

Conditions

Wound Healing; Burns

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Healthy volunteers

Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating "bone marrow stem cells" will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study.

Group Type: SHAM_COMPARATOR

Healthy volunteers

Intervention Type: GENETIC

Comparison of healthy volunteers to burn wounded volunteers

Burn volunteer

To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP \> 100 mm Hg systolic; heart rate \< 100 beats/minute; urine output \> 30 ml/hour; area of burn \< 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin \> 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension \> 1 year; smoking \> 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men \< 55 and women \< 65 years of age).Six 12 ml tubes will be taken at 5 time points

Group Type: ACTIVE_COMPARATOR

Burn volunteers

Intervention Type: OTHER

Comparison of burn wounded volunteers to healthy volunteers

Interventions

Healthy volunteers

Comparison of healthy volunteers to burn wounded volunteers

Intervention Type: GENETIC

Burn volunteers

Comparison of burn wounded volunteers to healthy volunteers

Intervention Type: OTHER

Other Intervention Names

Burn wounds

Eligibility Criteria

Inclusion Criteria

Recruitment of patients at the Johns Hopkins Regional Burn Center for study will be based upon the following clinical criteria:

• Second degree scald burn of 10 cm2
• Age between 14 to 75 years
• Burn area equal or less than 95% of Burn Surface Area (BSA)
• Body temperature between 98.5 and 101 degree F
• Informed consent for enrolment into study
• Spanish speaking patients will be included when we have a Spanish consent form available.

Exclusion Criteria

• First and third degree burn wounds
• Hemodynamic instability (SBP below 100, Heart Rate (HR) over 100, urine output less than 30 ml/hour
• Area of burn over 20% of BSA
• Hypothermia T<98.5 or Hyperthermia T>101 degree F
• Urine output less than 30 ml/hour
• Serum albumin less than 3 mg/ml.
• Subjects weighing less than 50 kg.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Harmon, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Countries

United States

References

Zhang X, Wei X, Liu L, Marti GP, Ghanamah MS, Arshad MJ, Strom L, Spence R, Jeng J, Milner S, Harmon JW, Semenza GL. Association of increasing burn severity in mice with delayed mobilization of circulating angiogenic cells. Arch Surg. 2010 Mar;145(3):259-66. doi: 10.1001/archsurg.2009.285.

Reference Type: DERIVED

PMID: 20231626 (View on PubMed)

Other Identifiers

NA_00018037

Identifier Type: -

Identifier Source: org_study_id